Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503984 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
A Phase 1 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00503984 is a Phase 1 study that was terminated before completion, run by University of Miami. The registered enrollment target is 22 participants.
The verdict
NCT00503984, a Phase 1 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Azacitidine can reverse clinical resistance to docetaxel through upregulation of Growth Arrest and DNA Damage inducible alpha (GADD45α) and other epigenetically regulated genes.
Interventions
- DRUG Docetaxel
- DRUG Azacitidine
- DRUG Prednisone
- DRUG Pegfilgrastim
- GENETIC GADD45α methylation and expression analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-05 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503984
The ClinicalTrials.gov registry entry for NCT00503984 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT00503984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503984 about?
NCT00503984 is a clinical study titled "A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients". Azacitidine can reverse clinical resistance to docetaxel through upregulation of Growth Arrest and DNA Damage inducible alpha (GADD45α) and other epigenetically regulated genes.
What is the current status of trial NCT00503984?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00503984?
The interventions under investigation include: Docetaxel (DRUG), Azacitidine (DRUG), Prednisone (DRUG), Pegfilgrastim (DRUG), GADD45α methylation and expression analysis (GENETIC).
Who is sponsoring clinical trial NCT00503984?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.